Business
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women
About this update from Femasys Inc.
[{"type":"text","content":"ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces that it has received CE mark certification and product approval from Health Canada, the Public Health Agency of Canada, for its compact, eco-friendly FemVue® MINI for fallopian tube assessment. “Our mission at Femasys has always been to develop cutting-edge technology that are safe, affordable, and accessible to address critical needs in women’s health,” said Kathy Lee-Sepsick, Femasys’ Founder, President, and CEO. “With the FemVue MINI, we are advancing an equally effective solution in a smaller footprint that is aligned with our initiative to be environmentally conscious demonstrating our commitment to sustainability.” The FemVue MINI is designed to provide the same high level of efficacy as its predecessor while embracing an eco-conscious form factor. By optimizing the size and environmental impact of FemVue, the Company aims to make a significant positive difference in resource management within women’s health care. The CE mark certification and Canadian approval of FemVue MINI open new opportunities for expanded access to advanced diagnostic technology for women across Europe and Canada. The FemVue MINI’s development is part of Femasys’ broader initiative to integrate environmentally impactful programs for its product lines. As Femasys continues to push the boundaries of innovation, the Company remains dedicated to balancing technological advancement with responsible resource management while maintaining high standards of environmental responsibility. About FemVueFemVue® is the first FDA-cleared product that creates natural contrast to allow for real time evaluation of the fallopian tubes with ultrasound in the GYN’s office that is safer and less costly than the alternative radiology exam. FemVue has also received regulatory approval in Canada and Europe. About FemasysFemasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed...